Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Hematological Oncology

• Publication date

  2013-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hon.2044PMID 23576184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma.

  2012cited by this paper
• Expression, Purification and Characterization of Recombinant Human Angiogenin in Pichia pastoris

  2012cited by this paper
• Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables

  2011cited by this paper
• Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth*

  2011cited by this paper
• Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer.

  2011cited by this paper
• High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

  2010cited by this paper
• Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis.

  2010cited by this paper
• Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases

  2010cited by this paper
• The Role of the TGF-β Coreceptor Endoglin in Cancer

  2010cited by this paper
• Soluble angiogenesis markers in gastric tumor patients.

  2009cited by this paper
• Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients.

  2008cited by this paper
• The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

  2008cited by this paper
• TGFbeta in Cancer.

  2008cited by this paper
• The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

  2008cited by this paper
• Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways.

  2007cited by this paper
• Transforming Growth Factor-β Binding Receptor Endoglin (CD105) Expression in Esophageal Cancer and in Adjacent Nontumorous Esophagus as Prognostic Predictor of Recurrence

  2007cited by this paper
• Cytokines and chemokines as regulators of angiogenesis in health and disease.

  2006cited by this paper
• Soluble endoglin contributes to the pathogenesis of preeclampsia

  2006cited by this paper
• Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

  2006cited by this paper
• BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma

  2006cited by this paper
• Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer

  2006cited by this paper
• Alterations in components of the TGF-beta superfamily signaling pathways in human cancer.

  2006cited by this paper
• Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes.

  2005cited by this paper
• Angiogenesis in life, disease and medicine

  2005cited by this paper
• Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.

  2004cited by this paper
• Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

  2004cited by this paper
• Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications

  2004cited by this paper
• VEGF‐R2 and neuropilin‐1 are involved in VEGF‐A‐induced differentiation of human bone marrow progenitor cells

  2004cited by this paper
• Elevated serum angiogenin in multiple myeloma.

  2003cited by this paper
• Differential levels of soluble endoglin (CD105) in myeloid malignancies

  2003cited by this paper
• CD105 is important for angiogenesis: evidence and potential applications

  2003cited by this paper
• Angiogenesis and apoptosis.

  2003cited by this paper
• Interleukin‐18

  2003cited by this paper
• Origin of endothelial progenitors in human postnatal bone marrow.

  2002cited by this paper
• Inducible expression of human endoglin during inflammation and wound healing in vivo

  2002cited by this paper
• Interleukin 18

  2001cited by this paper
• Endoglin: An accessory component of the TGF‐β‐binding receptor‐complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies

  2001cited by this paper
• Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

  2000cited by this paper
• Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer

  2000cited by this paper
• Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

  2000influential reference
• Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.

  1995cited by this paper

• High concentrations of soluble endoglin can inhibit BMP9 signaling in non-endothelial cells

  2023cites this paper
• The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis

  2018cites this paper
• Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model

  2018cites this paper
• Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma

  2017cites this paper
• Kinase inhibitors as potential agents in the treatment of multiple myeloma

  2016cites this paper
• Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease.

  2016cites this paper
• Role of Interleukin-18 in Thyroid tumorigenesis

  2016cites this paper
• Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

  2015cites this paper
• Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma

  2015influential citation
• Angiogenic markers in plasma cell myeloma patients treated with novel agents.

  2015cites this paper
• Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.

  2015cites this paper
• A suppressor role for soluble endoglin in cancer

  2015cites this paper
• Alterations in Hoffa’s fat pad induced by an inflammatory response following idealized anterior cruciate ligament surgery

  2015cites this paper
• The role of bone morphogenetic proteins in myeloma cell survival.

  2014cites this paper
• Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin

  2014cites this paper
• Prognostic impact of angiopoietin-2 in multiple myeloma

  2014cites this paper